Suomi - suomi - Fimea (Suomen lääkevirasto)

boehringer ingelheim animal health nordics a/s - ivermectin - injektioneste, liuos - 10 mg/ml - ivermektiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

boehringer ingelheim animal health nordics a/s - eprinomectinum - kertavaleluliuos - 5 mg/ml - eprinomektiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

orion corporation - rivastigmine - depotlaastari - 4.6 mg / 24 tuntia - rivastigmiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

orion corporation - rivastigmine - depotlaastari - 9.5 mg / 24 tuntia - rivastigmiini

Euroopan unioni - suomi - EMA (European Medicines Agency)

merial - eprinomectin - endektosidit - karja - hoitoa seuraavien loisten:ruoansulatuskanavan sukkulamadot (täysikasvuiset ja l4):- ostertagia ostertagi/lyrata, cooperia oncophora/surnabada, c. punctata, haemonchus contortus, trichostrongylus axel, t. colubriformis, bunostomum phlebotomum, nematodirus helvetianus, oesophagostomum radiatumlungworm (aikuiset ja l4):- dictyocaulus viviparuswarbles (lois-vaiheet):- hypoderma bovis, s. lineatummange punkit:- sarcoptes scabiei var. bovis täitä: linognathus vituli, haematopinus eurysternus, solenoptes capillatushorn lentää: haematobia irritansprevention ja reinfections seuraavat parasiitit:- dictyocaulus viviparus, ostertagia ostertagi/lyrata, trichostrongylus colubriformis, haemonchus contortus, ja bunostomum phlebotomum;- oesophagostomum radiatum, cooperia oncophora/surnabada, c. punctata ja trichostrongylus axel.

Suomi - suomi - Fimea (Suomen lääkevirasto)

orion corporation - rivastigmine - depotlaastari - 13.3 mg / 24 tuntia - rivastigmiini

Euroopan unioni - suomi - EMA (European Medicines Agency)

alnylam netherlands b.v. - lumasiran sodium - hyperoxaluria, primary - muut ruuansulatuselimistön sairauksien ja aineenvaihduntasairauksien lääkkeet, - treatment of primary hyperoxaluria type 1 (ph1) in all age groups.

Suomi - suomi - Fimea (Suomen lääkevirasto)

orion corporation - sildenafil citrate - tabletti, kalvopäällysteinen - 20 mg - sildenafiili

Euroopan unioni - suomi - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - prekursorisolujen lymfoblastinen leukemia-lymfooma - antineoplastiset aineet - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Euroopan unioni - suomi - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.